A PHARMACEOECONOMICS ANALYSIS OF A GOVERNMENT INITIATIVE OF DYSLIPIDEMIA IN CHINA DEVELOPED COMMUNITY CLINICAL PRACTICE
Author(s)
Xu J1, Ni W1, Zhuo Z1, Yu W1, Liu Y2, Shi R2, Yu W2
1Shenzhen Center for Chronic Disease Control, Guangdong, China, 2Pfizer, Beijing, China
OBJECTIVES: China Adult Dyslipidemia Management Program (CADMP) is a government initiative aiming to provide practical evidence of comprehensive management of cardiovascular disease for China national basic public health service policy by integrating lipid management with the existing hypertension and diabetes management. Shenzhen pilot is one of the three pilots among 5 subprojects of CADMP. The study is intended to assess the cost effectiveness of lipid management in CADMP Shenzhen. METHODS:
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PCV68
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now